ClinicalTrials.gg
CompletedNCT02466321Updated Jun 12, 2025Results posted

Anatomical Shoulder™ Inverse/Reverse Study

An interventional study of Inverse/Reverse Shoulder Arthroplasty in Cuff-tear Arthropathy, sponsored by Zimmer, GmbH. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Zimmer, GmbH · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 years after the study started (first participant enrolled May 2007, registered Jun 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to obtain outcomes data on the Anatomical Shoulder™ Inverse/Reverse System by analysis of standard scoring systems and radiographs.

Outcome data will be collected using the following standard scoring systems of which summary statistics will be provided:

  • Constant and Murley Score to evaluate clinical parameters such as range of motion, power, level of pain and functional ability.
Read the detailed description

This is a multi-centre, non-comparative, prospective post-market surveillance study involving orthopaedic surgeons skilled in shoulder replacement surgery. Each case enrolled will receive an Anatomical Shoulder™ Inverse/Reverse implant. All system components are CE-marked and commercially available. Patients will be selected according to the subject selection criteria.

All patients will undergo pre-operative, intra-operative and post-operative physical examination, radiographic evaluation according to the hospital's routine procedure and collection of quality of life metrics. Follow-up evaluations are to be conducted at either 6 weeks or 6 months (according to the hospital's standard care plan) and thereafter at 1, 2, 5 and 10 years post hospital discharge.

There are 5 study centres taking part in this project enrolling in total a maximum of 160 patients.

02

Conditions studied

  • Cuff-tear Arthropathy

Keywords

  • Inverse Reverse Shoulder
03

In context

Rotator Cuff Tear Arthropathy

57 studies on the registry are indexed under Rotator Cuff Tear Arthropathy; 14 are open to participants now.

This study's enrollment of 154 is above the median of 90 across 33 interventional studies indexed under Rotator Cuff Tear Arthropathy.

Browse Rotator Cuff Tear Arthropathy studies →

Lead sponsor

Zimmer, GmbH is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age - 18 years minimum.
  • Sex - male and female.
  • General Health - the patient should be able to undergo surgery and participate in a follow-up program based upon physical examination and medical history.
  • - patient or patient's legal representative has signed a Patient Informed Consent form.
  • Indications - Diagnosis of disease or trauma in the affected joint, including cuff-tear arthropathy, failure of prior rotator cuff surgery and irreparable rotator cuff tears associated with loss of glenohumeral stability with the indication for total shoulder arthroplasty.
  • The deltoid muscle has to be intact in all 3 parts (clavicular, acromial as well as spinal).

Exclusion criteria

Exclusion Criteria:

  • Patient is skeletally immature.
  • Patient is pregnant.
  • Patient is unwilling or unable to cooperate in a follow-up program.
  • Patient shows one of the following medical conditions - Chronic fracture, Acute fracture, Axillary nerve lesion, Severe loss of humeral or glenoid bone, Paralysis of the deltoid muscle, Active Infection
  • Patient requires one of the following medical interventions - Implant Revision, Glenoid bone grafting, Autografts
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Inverse / Reverse Shoulder

    Patient treated with a inverse / reverse shoulder device.

    Procedure: Inverse/Reverse Shoulder Arthroplasty

Interventions

  • ProcedureInverse/Reverse Shoulder Arthroplasty

    Implantation of the Anatomical Shoulder Inverse/Reverse System

06

What researchers measure

Primary outcomes

  1. Functional Performance

    Constant \& Murley Score. This evaluates clinical parameters such as range of motion, power, level of pain and functional ability. The score ranges from 0 - 100 with a higher score representing a better outcome.

    Time frame: 10 years

Secondary outcomes

  1. Survival (Kaplan-Meier)

    The Kaplan-Meier estimator is a non-parametric statistic used to estimate the survival function from lifetime data. It is used to measure the fraction of patients living (in this case without a revision surgery) for a certain amount of time after treatment. A higher score is a better outcome.

    Time frame: 10 years

07

Results

Posted Jun 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneAnatomical Shoulder Inverse/Reverse Prosthesis
Started154
Received study device153
Completed61
Not completed93
Withdrew: Death26
Withdrew: Revision6
Withdrew: Lost to follow-up60
Withdrew: Did not receive study device1

Outcome measures

PrimaryFunctional Performance

Constant \& Murley Score. This evaluates clinical parameters such as range of motion, power, level of pain and functional ability. The score ranges from 0 - 100 with a higher score representing a better outcome.

Time frame:
10 years
Reported as:
Mean · score on a scale
Functional Performance
score on a scaleInverse / Reverse Shoulder
Functional Performance57.9 ± 15.8
SecondarySurvival (Kaplan-Meier)

The Kaplan-Meier estimator is a non-parametric statistic used to estimate the survival function from lifetime data. It is used to measure the fraction of patients living (in this case without a revision surgery) for a certain amount of time after treatment. A higher score is a better outcome.

Time frame:
10 years
Reported as:
Count of units · Implants
Survival (Kaplan-Meier)
ImplantsInverse / Reverse Shoulder
Survival (Kaplan-Meier)147

Adverse events

Collected over AEs were collected from the time of surgery until study completion (up to 10 years). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inverse / Reverse Shoulder26/153 (17%)58/153 (37.9%)—
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventInverse / Reverse Shoulder
Death due to unrelated reasonsGeneral disorders26/153
Other general complication (not shoulder)General disorders16/153
Fracture of proximal humerusMusculoskeletal and connective tissue disorders5/153
Other shoulder related complicationMusculoskeletal and connective tissue disorders4/153
Glenoid implant looseningMusculoskeletal and connective tissue disorders3/153
Cardiac ArrhythmiaCardiac disorders2/153
DislocationMusculoskeletal and connective tissue disorders2/153
hematomaBlood and lymphatic system disorders2/153
AnemiaBlood and lymphatic system disorders1/153
Fracture of femoral neckMusculoskeletal and connective tissue disorders1/153

Baseline characteristics

154 participants were enrolled with signed informed consent whereas only 153 participants received the study device. 153 is the number that serves for the final analysis

Age, Continuous
Age, Continuous(years)Inverse / Reverse Shoulder
Mean74.4 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Inverse / Reverse Shoulder
Female97
Male56
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Inverse / Reverse Shoulder
Region of Enrollment
Region of Enrollment(participants)Inverse / Reverse Shoulder
Belgium19
United Kingdom13
Switzerland50
Germany71
BMI
BMI(kg/m2)Inverse / Reverse Shoulder
Mean27.2 ± 4.5
Height
Height(cm)Inverse / Reverse Shoulder
Mean165.0 ± 8.4
Weight
Weight(kg)Inverse / Reverse Shoulder
Mean74.1 ± 14.3
08

Study locations

5 sites
  • AZ Monica Antwerpen
    Antwerpen, Belgium
  • HELIOS ENDO-Klinik Hamburg
    Hamburg, Germany
  • Vitos Orthopädische Klinik Kassel
    Kassel, Germany
  • Uniklinik Balgrist
    Zürich, Switzerland
  • The Pennine Acute Hospital NHS Trust
    Manchester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2007 to primary completion in Feb 2022, 177 months.

Results were first posted in Jun 2025, 3 years 3 months after primary completion.

Of 20 interventional studies with no phase under Rotator Cuff Tear Arthropathy, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 72. This study's 177 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2015
First posted
Jun 9, 2015
StartActual
May 16, 2007
Primary completionActual
Feb 16, 2022
CompletionActual
Mar 11, 2024
Results first posted
Jun 12, 2025
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02466321
Lead sponsor
Zimmer, GmbH
Responsible party
Sponsor
First posted
Jun 9, 2015
Start date
May 16, 2007
Primary completion
Feb 16, 2022
Completion
Mar 11, 2024
Results posted
Jun 12, 2025
Last update
Jun 12, 2025

Study contacts

Elliott Goff, PhD
study chair · Zimmer Biomet, Jr. Clinical Project Lead

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion